Company / FCF Margin
Neurocrine Biosciences FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
26.2%
FY2025
5-year range
19.2% / 26.2%
FY2021-FY2025
Trend
+10.6%
vs FY2024
Sector context
#20 of 131
Health Care
What the data says
Neurocrine Biosciences's fcf margin of 26.2% is higher than 85% of companies in the Health Care sector (FY2025). FCF Margin has fluctuated over the past 9 years, ranging from -735.3% in FY2016 to 26.2% in FY2025.
Based on SEC 10-K filings.
26.2% in FY2025 with a 5-year CAGR of +5.4%. Top quartile in the Health Care sector.
Improved from 19.2% to 26.2% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +4.5pp
- 5-Year Change
- +5.4pp
- 10-Year Change
- -
Sector benchmark
Top 15% in Health CareTop 15% of 131This company 26.2% Sector average -646.9%
▼
+104.0% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 10.6% year-over-year.
- Currently 673.1pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 26.2% | +10.6% |
| FY2024 | 23.7% | +23.5% |
| FY2023 | 19.2% | -11.7% |
| FY2022 | 21.7% | +5.5% |
| FY2021 | 20.6% | -1.2% |
| FY2020 | 20.8% | +23.9% |
| FY2019 | 16.8% | -1.1% |
| FY2018 | 17.0% | - |
| FY2017 | - | - |
| FY2016 | -735.3% | -264.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026